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Background. The impact of inactivated polio vaccines (IPVs) on intestinal mucosal immune responses to live poliovirus is 
poorly understood.
Methods. In a 2014 phase 2 clinical trial, Panamanian infants were immunized at 6, 10, and 14 weeks of age with bivalent oral 
polio vaccine (bOPV) and randomized to receive either a novel monovalent high-dose type 2–specific IPV (mIPV2HD) or a stan-
dard trivalent IPV at 14 weeks. Infants were challenged at 18 weeks with a monovalent type 2 oral polio vaccine (mOPV2). Infants’ 
intestinal immune responses during the 3 weeks following challenge were investigated by measuring poliovirus type-specific neu-
tralization and immunoglobulin (Ig) A, IgA1, IgA2, IgD, IgG, and IgM antibodies in stool samples.
Results. Despite mIPV2HD’s 4-fold higher type 2 polio D–antigen content and heightened serum neutralization profile, 
mIPV2HD-immunized infants’ intestinal immune responses to mOPV2 challenge were largely indistinguishable from those receiv-
ing standard IPV. Mucosal responses were tightly linked to evidence of active infection and, in the 79% of participants who shed 
virus, robust type 2–specific IgA responses and stool neutralization were observed by 2 weeks after challenge.
Conclusions. Enhancing IPV-induced serum neutralization does not substantively improve intestinal mucosal immune 
responses or limit viral shedding on mOPV2 challenge.
Clinical Trials Registration. NCT02111135.
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The worldwide eradication of wild poliovirus type 2 was offi-
cially declared in September 2015 [1]. The signing of the decla-
ration marked a major milestone for the Global Polio Eradication 
Initiative, which has reduced the incidence of polio by >99.99% 
and contributed to the prevention of an estimated 16 million 
cases of paralytic poliomyelitis since its launch in 1988 [2, 3]. 
Additionally, the wild-type 2 eradication achieved a key pol-
icy prerequisite specified in the Polio Eradication and Endgame 
Strategic Plan 2013–2018, thus helping to set into motion the 
globally coordinated serotype-by-serotype withdrawal of oral 
polio vaccines (OPVs) from routine immunization programs [4]. 
Between 17 April and 1 May 2016, >150 countries and territories 
successfully implemented the first phase of OPV cessation: a glob-
ally synchronized “switch” from the trivalent oral polio vaccine 
(tOPV), which targets poliovirus types 1, 2, and 3, to the bivalent 
oral polio vaccine (bOPV), which lacks a type 2 component.
Though tOPV has acted as a strategic lynchpin for eradication 
efforts in developing country settings to date, the replacement 
of OPVs with their inactivated polio vaccine (IPV) counter-
parts is now warranted to achieve and sustain polio eradication. 
After administration via oral drops, the live attenuated viruses 
that comprise OPVs replicate at vaccinees’ nasopharyngeal and 
gastrointestinal mucosal surfaces but, in very rare cases, accu-
mulate genetic mutations that enable them to reacquire central 
nervous system virulence and/or heightened transmissibility 
(reviewed in [5]). The resulting circulating vaccine-derived 
polioviruses (cVDPVs) have caused >84% of the polio cases 
confirmed in 2017 (n = 80/95 year-to-date, as of 22 November 
2017) [6] and continued to be identified through environmental 
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surveillance (eg, detection of type 2 cVDPV in Nigeria in 2016 
[7]). Moreover, the type 2 component of live oral polio vaccine 
(OPV2) is estimated to have caused between 100 and 200 annual 
cases of vaccine-associated paralytic poliomyelitis (VAPP) [8] 
during each of the 16 intervening years between the last known 
case of wild poliovirus type 2 and the tOPV-bOPV switch [9]. 
IPV, in contrast, confers substantial protection against paralytic 
poliomyelitis (ie, seroconverting approximately 80% of infants 
10 weeks of age or older against all 3 types of polio after 2 doses 
[10]) and poses no associated risks of cVDPVs or VAPP.
Nevertheless, the ability of IPV immunization to generate a 
primary mucosal immune response with the capacity to inhibit 
live polio replication and thereby control poliovirus trans-
mission remains uncertain (for an in-depth review, see [11]). 
Several studies of poliovirus-specific immunoglobulin (Ig) 
A have provided evidence that prior exposure to live poliovi-
rus, via OPV or environmental exposure, appears to be import-
ant for inducing mucosal responses to IPV immunization [12, 
13], and a 2012 systematic review has demonstrated that, when 
delivered in the absence of OPV, IPV fails to statistically sig-
nificantly reduce children’s odds of having detectable fecal 
shedding following challenge with live attenuated polioviruses 
[14]. Emerging evidence from integrated bOPV/IPV trials, 
however, points to a potentially more significant role for IPV in 
the induction of mucosal immunity. For example, a 2013 trial 
of IPV-bOPV vaccine regimens in Chile reported significant 
inverse correlations between infants’ prechallenge poliovirus 
type 2–specific reciprocal serum neutralization titers and their 
fecal shedding indices (a composite metric accounting for both 
magnitude and duration of shedding) after mOPV2 challenge 
[15]. Moreover, in a 2013 Latin American trial in which a subset 
of infants was immunized with bOPV at 6, 10, and 14 weeks, 
vaccinees who received a supplementary dose of IPV at 14 
weeks had modestly higher type 2–specific stool neutralization 
at mOPV2 challenge and lower viral shedding indices in the 4 
weeks following challenge than their peers who received bOPV 
alone [16, 17]. While these studies suggest that, when delivered 
at standard doses as part of primary vaccine series, IPV may 
play a limited role in the induction of mucosal immunity, they 
also pose questions of whether it would be possible to enhance 
the mucosal immunogenicity of IPVs, such as via high-dose, 
adjuvanted, or intradermally administered vaccines, in order 
to mitigate shedding on subsequent exposure to live poliovirus.
To begin to address these questions, the current study investi-
gated the effect of a novel monovalent high-dose type 2–specific 
IPV (mIPV2HD) on mucosal immunity in infants immunized 
during an observer-blind, comparative, randomized, phase 2 
clinical trial in Panama [18]. In the trial, infants were immunized 
at 6, 10, and 14 weeks of age with bOPV and randomized 1:1 to 
receive a supplementary dose at 14 weeks of either mIPV2HD 
or standard trivalent IPV. All infants were then challenged with 
mOPV2 at 18 weeks of age and fecal samples were collected for 
the following 3 weeks [18]. For the principal trial results, Sáez-
Llorens and colleagues reported that, in comparison to immu-
nization with the standard IPV, mIPV2HD resulted in a higher 
proportion of infants with type 2 poliovirus seroconversion (ie, 
75% in IPV vs 93% in mIPV2HD; P <  .001) and no associated 
vaccine-related adverse events [18]. Nevertheless, 84% of infants 
in the trial had detectable mOPV2-related viral shedding despite 
having type 2–specific serum responses [18]. To examine intesti-
nal mucosal immune responses to mOPV2 challenge in greater 
detail, stool samples collected during the trial were assayed for 
type-specific polio pseudovirus neutralization and for total 
and type-specific IgA, IgA1, IgA2, IgD, IgG, and IgM. Mucosal 
immune markers were compared by vaccine group assignment 
and by participants’ control of mOPV2-associated viral shedding.
METHODS
Study Design and Participants
The design of the phase 2, observer-blind, comparative, random-
ized controlled trial (NCT02111135), which enrolled infants 
at a single center in Panama City, Panama, between 14 April 
and 9 May 2014, has been described in detail previously [18]. 
Participants included healthy infants (restricted to 1 per house-
hold) aged 5–8 weeks at enrollment and excluded infants who 
(i) had been previously vaccinated against poliovirus; (ii) had a 
confirmed or suspected immunodeficiency; (iii) had a low birth 
weight (ie, <2500 g); (iv) had a known allergy to any component 
of the vaccines; or (v) resided in a household with someone who 
had received OPV within the previous 3 months or was scheduled 
to receive OPV during the study period. In the trial, all enrolled 
infants were vaccinated with 3 serial doses of bOPV (Sanofi 
Pasteur, Lyon, France) at approximately 6, 10, and 14 weeks of 
age and were randomized 1:1 to receive 1 additional intramus-
cular dose of either mIPV2HD formulated with 32 D-antigen 
units of poliovirus type 2 (Bilthoven Biologicals, Bilthoven, 
Netherlands) or standard IPV with 40, 8, and 32 D-antigen units 
of poliovirus types 1, 2, and 3, respectively (Sanofi Pasteur, Lyon, 
France) at the time of the third bOPV administration. All infants 
were challenged with a single dose of mOPV2 at 18 weeks of age. 
Serum samples were collected at 6, 14, 15, 18, and 19 weeks of 
age; stool samples were collected at 19, 20, and 21 weeks of age. 
See Supplementary Table 1 for study schema.
Laboratory Procedures
Intestinal immunity against type 2 polio was evaluated from 
infant stool samples (5–10 g), which were shipped frozen first 
to the Polio and Picornavirus Laboratory Branch at the US 
Centers for Disease Control and Prevention (CDC) for the eval-
uation of viral shedding and subsequently to the Geisel School 
of Medicine at Dartmouth College for the current investigation. 
Poliovirus shedding is expressed as the log10 50% cell culture 
infective dose (CCID50) per gram of stool, as described in the 
primary study [18]; samples with shedding below the limit 
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of detection were recorded at a log10 CCID50 of zero. Vaccine 
group assignments were unblinded to the Dartmouth team only 
after sample testing and initial statistical analyses were com-
pleted. Mucosal immune responses were evaluated by methods 
described previously [17, 19, 20]. Stool neutralization titers 
were determined by limiting dilution inhibition of luciferase-la-
beled type-specific polio pseudoviruses in vitro as previously 
described [20] and expressed as the log2 reciprocal dilution 
needed to achieve 60% neutralization. Titers >1:512 (ie, the 
highest dilution tested) were recorded at 1:1024; those <1:4 (ie, 
the lowest dilution tested) were recorded at 1:2. Levels of IgA, 
IgA1, IgA2, IgD, IgG, and IgM in stool specimens were quanti-
fied relative to standard curves using a multiplex antibody plat-
form as previously described [19] (see Supplementary Figure 1 
for an overview of the method and Supplementary Table 2 for 
updated reagent manufacturing information). Relative concen-
tration units below the limit of detection were recorded at a 
concentration of half the lowest detectable measurement of the 
given immunoglobulin. Serotype-specific serum neutralization 
activity was evaluated in the primary study at the CDC using 
the WHO standard microneutralization assay [21].
Statistical Analyses
For the statistical analyses, infants were categorized both by 
vaccine group assignment (ie, bOPV-bOPV-bOPV+mIPV2HD 
or bOPV-bOPV-bOPV+IPV) and by shedding (ie, whether 
the infant had any or no viral shedding detectable during the 
postchallenge study visits). Differences in the distributions of 
log10 viral shedding, log2 serum and stool neutralization titers, 
and log10 mucosal immunoglobulin relative concentration units 
across groups were evaluated using the Mann–Whitney U test. 
Differences in the proportions of infants with detectable levels of 
log10 viral shedding, log2 serum and stool neutralization titers, 
and log10 mucosal immunoglobulin relative concentration units 
across groups were compared using Pearson χ2 test. Correlations 
between serum neutralization and viral shedding, neutraliza-
tion, and IgA in stool were estimated using Spearman rank cor-
relation coefficients and visualized by plotting the median and 
interquartile ranges of each of the variables vs the mean for each 
quintile of serum neutralization. Longitudinal patterns were 
investigated using scatter plots with local regression (LOESS) 
curves and 95% confidence intervals (CIs) fitted by shedding 
category; mean differences between groups were estimated at 1, 
2, and 3 weeks postchallenge using linear regressions adjusted 
for vaccine group assignment. Pairwise correlations between 
mucosal antibody concentrations and neutralization titers in 
stool samples, as well as correlations between each of these 
intestinal immune markers and the magnitude of viral shedding 
(CCID50), were estimated after stratification by shedding group 
with Spearman rank correlation coefficients and visualized in 
matrices using the “corrplot” R package, version 0.77 [22]. All 
P values are from 2-sided statistical tests, and all analyses were 
performed using Stata software version 13.0 (StataCorp LP, 
College Station, Texas) and R software, version 3.2.5.
Ethics
The study was approved by the Committee for the Protection 
of Human Subjects at Dartmouth College, Hanover, New 
Hampshire, and by the local ethical review board of the Hospital 
del Niño “Dr José Renán Esquivel,” Panama City, Panama, and 
was conducted in accordance with the Declaration of Helsinki, the 
International Conference on Harmonisation guideline for Good 
Clinical Practice, and the codes and regulations of Panama regard-
ing research on human subjects. The initial consenting included 
provisions for the use of samples in future polio-related studies, 
and the reconsenting of participants was judged unnecessary.
RESULTS
Intestinal immune responses to mOPV2 challenge were eval-
uated in 300 fecal samples collected from a randomly selected 
subset of 100 infants, representing approximately half of the 
participants in the primary study. The participants included 53 
infants immunized with bOPV-bOPV-bOPV+mIPV2HD and 
47 infants immunized with bOPV-bOPV-bOPV+IPV. In stool 
samples collected at 19 weeks of age, the mean total concen-
trations for the mucosal antibodies were 620 000  ng/mL for 
IgA, 570 ng/mL for IgM, 27 ng/mL for IgD, and 1.7 ng/mL for 
IgG. Consistent with prior reports on duodenal secretions [23], 
poliovirus-specific IgG was not detected in any of the fecal sam-
ples. Although this study’s analyses focused on type 2–specific 
intestinal responses, it bears noting that infants in both vaccine 
groups exhibited robust mucosal immunity against poliovirus 
types 1 and 3, with high levels of type 1– and type 3–specific 
intestinal neutralization and IgA measured up to 7 weeks after 
the third dose of bOPV (Table 1).
Effects of mIPV2HD on Serum Neutralization and Mucosal Immune 
Responses to mOPV2 Challenge
Although infants in the mIPV2HD group had significantly 
enhanced type 2 serum neutralization at the time of mOPV2 
challenge compared with the IPV group (P < .001; Table 1), the 
markers of type 2–specific intestinal mucosal immunity mea-
sured in this investigation did not differ substantively by vac-
cine group assignment (Tables 1 and 2). As previously reported 
[18] and observed here, similar magnitudes of viral shed-
ding occurred in both trial arms during the 3 follow-up visits 
(Table 1). Data collected on type 2–specific stool neutralization, 
IgA, IgA1, IgA2, IgD, and IgM similarly demonstrated com-
parable intestinal responses to mOPV2 challenge between the 
mIPV2HD and standard IPV groups in cross-sectional analyses 
at weeks 1, 2, and 3 postchallenge (Tables 1 and  2). In analyses 
that combined vaccine groups, type 2–specific serum neutral-
ization titers were not associated with fecal levels of type 2–spe-
cific viral shedding, stool neutralization, nor IgA (Figure 1).
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Associations of mOPV2 Shedding With Serum Neutralization and 
Mucosal Immune Markers
Approximately one-fifth of infants (n = 11/53 in the mIPV2HD 
group; n = 10/47 in the IPV group) shed no detectable mOPV2 
virus during the postchallenge study visits. Relative to the non-
shedders, the infants who would go on to shed virus exhibited 
modestly lower mean type 2–specific serum neutralization 
activity during 4 of the study visits prior to challenge and sig-
nificantly higher neutralization at the visit 1 week after challenge 
(P = .01; Table 3). Shedding status was also associated with the 
kinetics of the intestinal mucosal immune response to mOPV2 
challenge. Whereas shedders (n = 79) and nonshedders (n = 21) 
had similar levels of type 2–specific stool neutralization and 
mucosal antibodies 1 week after challenge, the groups markedly 
diverged by 2 and 3 weeks after challenge (Figure 2; Tables 2 
and 3). The shedding group had statistically significantly higher 
mean levels of type 2–specific stool neutralization activity, 
IgA, and IgA1 during weeks 2 and 3 postchallenge (Figure 2), 
and the differences in mucosal responses by shedding status 
were consistent regardless of IPV group assignment (Table  3; 
Supplementary Figure 2). In addition, relative to nonshedding 
infants, a larger proportion of shedding infants had detectable 
type 2–specific IgA1, IgA2, and IgM responses at 3 weeks after 
challenge (Table 2). Type 2–specific IgD was detectable in the 
majority of participants, but no significant differences by shed-
ding status were observed for this parameter across any of the 
time nodes (Table 2).
Correlates of Mucosal Immunity to Type 2 Poliovirus
With the aim of exploring how intestinal antibody concen-
trations related to each other and to neutralizing activity over 
time, we examined pairwise correlations in the 2 shedding 
groups at 1, 2, and 3 weeks postchallenge (Supplementary 
Figure 3). Overall, type 2–specific IgA was the strongest cor-
relate of stool neutralization (Spearman ρ at 2 weeks: 0.74, 
P < .0001) and explained approximately half of its variance in 
Table 1. Polio Type-Specific Immune Profiles of Infants Previously Immunized With Bivalent Oral Polio Vaccine (bOPV)–bOPV-bOPV + Monovalent High-
Dose Type 2–Specific Inactivated Polio Vaccine (n = 53) or bOPV-bOPV-bOPV + Trivalent Inactivated Polio Vaccine (n = 47)
Weeks of 
Age
Weeks After 
Challenge
Median (IQR)
P Value,  
Mann–Whitney 
U Test
Proportion With Detectable 
Marker, No. (%)
P Value, χ2 
Test 
bOPV-bOPV- 
bOPV+mIPV2HD
bOPV-bOPV- 
bOPV+IPV
bOPV-bOPV- 
bOPV+mIPV2HD
bOPV-bOPV- 
bOPV+IPV
Type 2 Serum 6 … 4.5 (3.2–5.5) 3.5 (2.5–5.5) .10 42 (79) 33 (70) .30
neutralization, 14 … 2.8 (2.5–3.8) 2.5 (2.5–3.2) .18 31 (58) 21 (45) .17
log2 titer 15 … 8.5 (7.2–9.5) 5.2 (4.2–7.2) <.001 52 (98) 46 (98) .93
18 … 7.5 (6.2–9.2) 5.8 (3.8–7.2) <.001 53 (100) 43 (91) .03
19 1 8.5 (7.2–9.5) 7.5 (6.2–8.8) .02 53 (100) 47 (100) …
Viral shedding, 19 1 5.0 (2.8–6.2) 4.0 (0–5.7) .10 42 (79) 33 (70) .30
log10 CCID50 20 2 2.8 (0–4.8) 2.8 (0–4.1) .54 31 (58) 28 (60) .91
21 3 0 (0–3.0) 0 (0–4.5) .22 19 (36) 22 (47) .27
Stool neutralization, 19 1 6.3 (4.6–7.3) 5.6 (3.0–7.1) .52 44 (83) 38 (81) .78
log2 titer 20 2 8.2 (7.2–10) 7.8 (6.3–8.7) .08 52 (98) 44 (94) .25
21 3 8.4 (7.7–10) 8.0 (6.3–10) .10 51 (96) 42 (89) .18
Stool IgA, log10 relative 19 1 0.9 (0.2–1.6) 0.7 (-0.2–1.4) .44 50 (94) 44 (94) .88
concentration units 20 2 2.1 (1.5–2.5) 1.6 (1.0–2.1) .05 53 (100) 47 (100) …
21 3 1.8 (1.2–2.8) 1.6 (0.4–2.5) .35 53 (100) 47 (100) …
Type 1 Stool neutralization, 19 1 7.2 (5.0–8.0) 7.4 (5.2–8.2) .49 46 (87) 46 (98) .04
log2 titer 20 2 8.1 (7.2–8.6) 8.3 (7.1–10) .53 52 (98) 46 (98) .93
21 3 8.2 (7.1–10) 7.9 (7.0–9.0) .45 51 (96) 43 (91) .32
Stool IgA, log10 relative 19 1 –0.3 (–1.3 to 0.6) 0 (–1.3 to 0.7) .27 37 (70) 35 (75) .61
concentration units 20 2 0.3 (–0.3 to 0.8) 0.3 (–0.3 to 0.8) .74 49 (92) 43 (91) .86
21 3 0.3 (–0.5 to 0.8) 0.3 (–0.7 to 0.8) .75 49 (92) 39 (83) .15
Type 3 Stool neutralization, 19 1 6.9 (4.2–8.0) 6.5 (3.5–8.2) .58 48 (91) 41 (87) .60
log2 titer 20 2 8.0 (6.3–10) 7.4 (4.8–8.7) .23 50 (94) 44 (94) .88
21 3 8.1 (6.1–10) 6.9 (4.4–8.5) .06 49 (92) 40 (85) .24
Stool IgA, log10 relative 19 1 1.6 (0.9–2.2) 1.8 (1.1–2.1) .83 52 (98) 47 (100) .34
concentration units 20 2 1.9 (1.4–2.2) 1.7 (1.2–2.1) .37 53 (100) 47 (100) …
21 3 1.8 (1.4–2.3) 1.8 (1.0–2.2) .44 52 (98) 47 (100) .34
Abbreviations: bOPV, bivalent oral polio vaccine; CCID50, 50% cell culture infectious dose; IgA, immunoglobulin A; IPV, trivalent inactivated polio vaccine; mIPV2HD, monovalent high-dose 
inactivated polio type 2 vaccine.
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a univariate linear regression (r2 at 2 weeks: 0.47). Focusing on 
only the 79 infants in the shedding group, a pattern between 
the levels of immune markers and the magnitude of viral shed-
ding emerged. At 1 week after challenge, there was no asso-
ciation between viral shedding and type 2–specific serum 
neutralization (Spearman ρ: 0.00, P =  .99; see Supplementary 
Figure 4 for detailed scatter plot). Out of the intestinal immune 
markers, only type 2–specific IgD was statistically significantly 
inversely associated with viral shedding at 1 week (Spearman 
ρ: –0.23, P = .04; Figure 3). By weeks 2 and 3 after challenge, 
the inverse correlation between viral shedding and type 2–spe-
cific IgD waned as the inverse correlations between shedding 
and type 2–specific IgA, IgA1, and stool neutralization titers 
became stronger (P < .005 for all).
DISCUSSION
In infants previously immunized with 3 doses of bOPV plus 
either mIPV2HD or standard IPV, the current study delineates 
intestinal immune response to live oral polio vaccine challenge 
using state-of-the-art multiplex bead–based tools for quanti-
tating antibodies and polio pseudovirus neutralization assays 
for assessing function. The results of this analysis provide com-
pelling evidence that enhancing serum neutralization with a 
high-dose IPV in the primary immunization series does not 
substantively improve mucosal protection upon subsequent 
exposure to live polioviruses. Despite mIPV2HD’s 4-fold higher 
concentration of type 2 polio antigen and 3-fold higher postvac-
cination median serum antibody titers, mIPV2HD-immunized 
infants’ intestinal immune responses to challenge did not differ 
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Figure 1. Correlations between polio type 2–specific neutralization titers measured in serum at the time of challenge and monovalent type 2 oral polio vaccine (mOPV2) 
viral shedding (50% cell culture infective dose [CCID50]) (A), polio pseudovirus type 2–specific neutralization titers (B), and polio type 2–specific immunoglobulin A (IgA) levels 
(C), all measured in stool at 1 week after mOPV2 challenge (ie, 19 weeks of age). Black squares and bars indicate the median and interquartile ranges of the variables on 
the y-axes within each quintile of serum neutralization plotted against the mean serum neutralization within each quintile. Red markers indicate infants in the bivalent oral 
polio vaccine (bOPV)–bOPV-bOPV + trivalent inactivated polio vaccine (IPV) group (n = 47); gray markers indicate infants in the bOPV-bOPV-bOPV + monovalent high-dose 
type 2–specific IPV (mIPV2HD) group (n = 53). Circle-shaped markers indicate infants with any detectable viral shedding during postchallenge study visits (n = 79); X-shaped 
markers indicate infants with no detectable viral shedding during postchallenge study visits (n = 21). 
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from those of the standard IPV group in terms of polio type 2–
specific IgA, IgA1, IgA2, IgD, IgG, or IgM antibody responses 
or neutralization at any time during the 3 weeks after mOPV2 
challenge.
Overall, the current findings are consistent with earlier 
studies demonstrating a limited role for IPV—and specifically 
enhanced potency IPV [24]—in the induction of mucosal anti-
bodies and inhibition of poliovirus shedding in individuals with 
no previous exposure to live virus [12–18, 23, 25]. For exam-
ple, a 1991 trial in a Maryland cohort showed that, despite hav-
ing significantly higher mean prechallenge serum neutralizing 
antibody levels, children immunized with 3 doses of enhanced 
potency IPV at 2, 4, and 18  months of age were significantly 
more likely to shed virus upon mOPV1 challenge than their 
peers who received OPV at the same time points (percentage 
shedding: 63% vs 25%) [24]. Moreover, a 2001 trial in a Sabin 
virus–free Cuban population found that the percentage of 
infants who shed any type of poliovirus after tOPV challenge 
was >90% regardless of whether the infants had received zero, 2, 
or 3 prior doses of IPV [25]. Moving forward, further research 
will be valuable for understanding whether administering stan-
dard or high-dose IPVs at later ages and/or with repeated doses 
could overcome these limitations and have the potential to aug-
ment the mucosal immunogenicity of inactivated vaccines.
Because the inactivated vaccines had a limited impact on type 
2 viral shedding after challenge, this study provided a unique 
opportunity to explore the kinetics of the mucosal antibody 
response to live poliovirus and to gain novel insight into the cor-
relates of intestinal immunity against polio. In line with prior 
investigations of intestinal immunity [17, 19, 23], these data sug-
gest that IgA, and the IgA1 subclass in particular (as previously 
noted in serum responses to poliovirus in naive individuals [26]), 
8
10
A B
C D
Non-shedding (n = 21)
Shedding (n = 79)
6
4
L
og
2 
R
ec
ip
ro
ca
l T
ite
r 
of
 T
yp
e 
2 
St
oo
l N
eu
tr
al
iz
at
io
n
2
0
1 2
Weeks After mOPV2 Challenge
3 L
og
10
 R
el
at
iv
e 
C
on
ce
nt
ra
tio
n 
U
ni
ts
 o
f T
yp
e 
2 
St
oo
l I
gA
–1
0
1
2
3
4
L
og
10
 R
el
at
iv
e 
C
on
ce
nt
ra
tio
n 
U
ni
ts
 o
f T
yp
e 
2 
St
oo
l I
gA
2
–1
0
1
2
3
4
1 2
Weeks After mOPV2 Challenge
3
1 2
Weeks After mOPV2 Challenge
3 1 2
Weeks After mOPV2 Challenge
3L
og
10
 R
el
at
iv
e 
C
on
ce
nt
ra
tio
n 
U
ni
ts
 o
f T
yp
e 
2 
St
oo
l I
gA
1
–1
0
1
2
3
4
Figure 2. Polio type 2–specific intestinal immune responses to monovalent type 2 oral polio vaccine (mOPV2) challenge in infants with any (n = 79) and no (n = 21) viral shed-
ding detectable during postchallenge study visits: stool neutralization titers (A), immunoglobulin (Ig) A levels (B), IgA1 levels (C), and IgA2 levels (D), all measured in stool at 
1–3 weeks after mOPV2 challenge (ie, 19–21 weeks of age). Data represent the combined responses of both vaccine groups. Scatter plots indicate individual measurements. 
LOESS curves (95% confidence interval) were fitted by shedding category. Abbreviations: Ig, immunoglobulin.
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is likely the primary mediator of intestinal neutralization of polio 
pseudoviruses. Specifically, IgA, IgA1, and intestinal neutraliza-
tion responded by 2 weeks after challenge in both IPV groups, 
and marker levels were inversely correlated with the amount of 
virus recovered from the 79% of children with detectable shed-
ding. In infants with no detectable viral shedding, levels of IgA, 
IgA1, and neutralization remained flat across the 3 postchallenge 
study visits. Intriguingly, low levels of poliovirus-specific IgD 
were widely detectable in vaccinated infants and appeared to be 
inversely correlated with shedding 1 week postchallenge, sug-
gesting a potential involvement of IgD in immune surveillance 
and/or the early neutralizing response (for a broader overview of 
IgD and mucosal immunity, see [27]). Type 2–specific IgA2 and 
IgM became detectable in a substantial proportion of individuals 
with active infection, whereas type 2–specific IgG was detectable 
in no fecal samples.
While the present study described the longitudinal mucosal 
antibody response to oral polio vaccine challenge with unprec-
edented detail, the chief limitation was that stool samples were 
only collected in the original trial from infants during the 3 
weeks following mOPV2 challenge. Without fecal samples 
collected from infants at the time of and in the weeks imme-
diately following IPV immunization, this study was unable to 
fully assess and compare the mIPV2HD and IPV vaccines’ pri-
mary intestinal immunogenicity (ie, measured in terms of stool 
neutralization and antibody levels in lieu of viral shedding). 
Moreover, without fecal samples collected prior to infants’ first 
exposure to live attenuated type 2 poliovirus (ie, at the time of 
mOPV2 challenge), the study was unable to evaluate the change 
in infants’ immune parameters relative to pre-OPV levels or to 
compare indicators of baseline intestinal immunity between 
shedders and nonshedders. The second key limitation was that 
the original trial did not include a bOPV-only control group and, 
thus, obviated investigation of whether the mIPV2HD and IPV 
groups primed type 2 mucosal responses to live virus relative to 
children with no prior polio type 2 immunological experience. 
A third limitation is that tOPV was still in use for Panamanian 
routine immunization in 2014, and it remains plausible that the 
relatively large nonshedding group (21%) may have been influ-
enced by inadvertent exposure to OPV-derived strains.
Table 2. Presence of Polio Type 2–Specific Mucosal Antibodies Measured in Stool Samples Collected From Infants During Postchallenge Study Visits
Total
No.
Proportion With Detectable Type 2–Specific Antibody
IgA,
No. (%)
P Value,
χ2 Test
IgA1,
No. (%)
P Value,
χ2 Test
IgA2,
No. (%)
P Value,
χ2 Test
IgD,
No. (%)
P Value,
χ2 Test
IgM,
No. (%)
P Value,
χ2 Test
1 week postchallenge (19 wk of age) 
 Vaccine group .88 .895 .748 .520 .571
  bOPV-bOPV- 
bOPV+mIPV2HD
53 50 (94%) 13 (25%) 3 (6%) 34 (64%) 11 (21%)
  bOPV-bOPV- 
bOPV+IPV
47 44 (94%) 11 (23%) 2 (4%) 33 (70%) 12 (26%)
 Shedding during 
follow-up
.79 .982 .285 .280 .099
  Shedding 79 74 (94%) 19 (24%) 3 (4%) 55 (70%) 21 (27%)
  Nonshedding 21 20 (95%) 5 (24%) 2 (10%) 12 (57%) 2 (10%)
2 weeks postchallenge (20 wk of age)
 Vaccine group … .129 .597 .571 .075
  bOPV-bOPV- 
bOPV+mIPV2HD
53 53 (100%) 26 (49%) 10 (19%) 42 (79%) 25 (47%)
  bOPV-bOPV- 
bOPV+IPV
47 47 (100%) 16 (34%) 7 (15%) 35 (74%) 14 (30%)
 Shedding during 
follow-up
… .004 .093 .206 .009
  Shedding 79 79 (100%) 39 (49%) 16 (20%) 63 (80%) 36 (46%)
  Nonshedding 21 21 (100%) 3 (14%) 1 (5%) 14 (67%) 3 (14%)
3 weeks postchallenge (21 wk of age)
 Vaccine group … .594 .416 .124 .631
  bOPV-bOPV- 
bOPV+mIPV2HD
53 53 (100%) 22 (42%) 12 (23%) 45 (85%) 17 (32%)
  bOPV-bOPV- 
bOPV+IPV
47 47 (100%) 22 (47%) 14 (30%) 34 (72%) 13 (28%)
 Shedding during 
follow-up
… <.001 .013 .338 .021
  Shedding 79 79 (100%) 43 (54%) 25 (32%) 64 (81%) 28 (35%)
  Nonshedding 21 21 (100%) 1 (5%) 1 (5%) 15 (71%) 2 (10%)
Abbreviations: bOPV, bivalent oral polio vaccine; Ig, immunoglobulin; IPV, trivalent inactivated polio vaccine; mIPV2HD, monovalent high-dose inactivated polio type 2 vaccine.
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In conclusion, to prepare for the transitional and post-OPV 
phase of the polio endgame, it is important to appraise can-
didate immunization strategies in terms of their potential to 
both prevent paralytic polio and interrupt transmission of 
viruses. The findings of the current study reinforce the con-
cept that, although vaccines such as mIPV2HD that induce 
strong serum neutralization are likely to be highly valuable 
for minimizing paralytic poliomyelitis risks [18], enhanced 
potency inactivated vaccines, on their own, are not likely 
to be effective at inducing the intestinal immune responses 
that are necessary to control poliovirus shedding and curtail 
outbreaks.
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Figure 3. Correlations between levels of monovalent type 2 oral polio vaccine (mOPV2) viral shedding (50% cell culture infectious dose) and levels of polio type 2–specific 
mucosal antibodies and neutralization titers measured in stool collected at 1 week (A), 2 weeks (B), and 3 weeks (C) after mOPV2 challenge from infants with any viral shed-
ding detectable during postchallenge study visits (n = 79). Spearman rank correlation coefficients were estimated from the combined responses of both vaccine groups. The 
narrowness of the ellipse and intensity of the color indicate the strength of a given correlation coefficient. The corresponding numerical values are defined by the vertical bar 
on the right. *P < .05; **P < .005. Abbreviations: CCID50, 50% cell culture infectious dose, Ig, immunoglobulin; Neutr., neutralization.
Table 3. Polio Type 2–Specific Immune Responses to Monovalent Type 2 Oral Polio Vaccine Challenge in Infants With Any (n = 79) and No (n = 21) Viral 
Shedding Detectable During Postchallenge Study Visits
Type 2–Specific Immune Markers Weeks of Age Weeks After Challenge
Mean Difference by Shedding Status (95% CI) After 
Adjustment for Vaccine Group P Value, Wald Test
Serum neutralization, log2 titer 6 … –0.78 (–1.59 to .03) .06
14 … –0.50 (–1.15 to .14) .12
15 … –0.46 (–1.43 to .51) .35
18 … –0.89 (–1.87 to .09) .08
19 1 1.11 (.27–1.94) .01
Stool neutralization, log2 titer 19 1 –0.27 (–1.49 to .94) .66
20 2 1.93 (1.03–2.83) <.001
21 3 3.41 (2.43–4.39) <.001
Stool IgA, log10 relative concentration 
units
19 1 –0.17 (–.67 to .33) .50
20 2 1.26 (.88–1.63) <.001
21 3 1.50 (1.06–1.95) <.001
Stool IgA1, log10 relative concentra-
tion units
19 1 –0.04 (–.28 to .20) .75
20 2 0.57 (.15–.99) .008
21 3 0.87 (.43–1.32) <.001
Stool IgA2, log10 relative concentra-
tion units
19 1 –0.13 (–.35 to .08) .22
20 2 0.26 (–.11 to .63) .17
21 3 0.49 (.06–.93) .03
Stool IgD, log10 relative concentration 
units
19 1 0.13 (–.06 to .31) .17
20 2 0.11 (–.05 to .28) .18
21 3 0.07 (–.09 to .23) .41
Stool IgM, log10 relative concentra-
tion units
19 1 0.16 (–.01 to .32) .06
20 2 0.29 (.09–.50) .005
21 3 0.24 (.04–.43) .02
Mean differences comparing the shedders to the nonshedders (reference group) were estimated for each time node using linear regressions with adjustment for vaccine group assignment. 
Abbreviations: CI, confidence interval; Ig, immunoglobulin.
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Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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